Latest From Alaric DeArment
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.